Eli Lilly Announces Executive Leadership Changes to Propel Future Growth
Eli Lilly and Company (NYSE: LLY) today announced a series of executive leadership transitions designed to strengthen its ability to deliver sustained, long-term growth and expand access to its medicines for millions of people worldwide.
Over the past several years, Lilly has achieved remarkable growth, particularly within its U.S. and cardiometabolic health businesses. Looking ahead, the company anticipates continued momentum in these areas alongside further advancement of its product pipeline. To support this next phase of growth, Lilly is sharpening its leadership focus on the U.S. market and its global therapeutic areas.
Effective with these changes:
- Ilya Yuffa, currently executive vice president and president, Lilly International, will assume the role of executive vice president and president, Lilly USA and Global Customer Capabilities. Yuffa will oversee the U.S. business, leading sales, marketing, and commercial operations across all marketed products, and will steer the commercialization of upcoming U.S. product launches.
- Patrik Jonsson, currently executive vice president and president, Lilly Cardiometabolic Health, and president, Lilly USA, will become executive vice president and president, Lilly International. Jonsson’s leadership has driven significant growth and market leadership in Lilly’s cardiometabolic and U.S. businesses. His deep expertise in global launches positions him to accelerate Lilly’s international growth.
- Kenneth Custer, Ph.D., currently general manager of Lilly Canada, will be promoted to executive vice president and president, Lilly Cardiometabolic Health, and will join the company’s executive committee. A 16-year veteran of Lilly, Custer has built a diverse career spanning sales, marketing, and early-stage drug development. He played a key role in advancing critical immunology and diabetes programs, including the development of tirzepatide, and has held senior positions in portfolio strategy and business development.
“Thanks to Patrik’s outstanding leadership, Lilly’s cardiometabolic and U.S. businesses have seen tremendous growth in recent years,” said David A. Ricks, Lilly’s chair and CEO. “With these leadership transitions, we are enhancing our focus and positioning the company to reach even greater heights. I have full confidence that Patrik, Ilya, and Ken will continue advancing our mission to discover, develop, and deliver medicines that help people live longer, healthier lives.”
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable
